Key takeaways
Foundayo and the Wegovy pill are two oral GLP-1s approved for weight loss.
The Wegovy pill tends to lead to more weight loss (13.6%) than Foundayo (11.2%), according to separate studies.
While they’re both taken daily, the two drugs differ in how you take them: Foundayo can be taken any time of day, with or without food, while the Wegovy pill follows a stricter dosing schedule (involving fasting).
Both Foundayo and the Wegovy pill share similar pricing ($149–$299 per month on Ro) and side effects (e.g. nausea, vomiting, diarrhea, constipation).
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Foundayo and the Wegovy pill are two oral GLP-1s approved for weight loss.
The Wegovy pill tends to lead to more weight loss (13.6%) than Foundayo (11.2%), according to separate studies.
While they’re both taken daily, the two drugs differ in how you take them: Foundayo can be taken any time of day, with or without food, while the Wegovy pill follows a stricter dosing schedule (involving fasting).
Both Foundayo and the Wegovy pill share similar pricing ($149–$299 per month on Ro) and side effects (e.g. nausea, vomiting, diarrhea, constipation).
With the Wegovy pill (semaglutide) and Foundayo (orforglipron) now available, it’s natural to ask: Which oral GLP-1 for weight loss might be best for me? While a healthcare provider is best equipped to help you answer that question, learning how the two pills stack up can make it easier to weigh your options.
Read on as we compare Foundayo vs. the Wegovy pill: their key differences, similarities, and weight loss benefits.
Foundayo vs. Wegovy pill: at a glance
While they have different active ingredients, Foundayo and the Wegovy pill work similarly since they’re both GLP-1 medications. GLP-1s work by:
Slowing down digestion, so you feel full sooner and longer
Balancing blood sugar levels after you eat, which prevents hunger spikes
Decreasing appetite, so you eat less and feel more in control of your eating
Here’s a quick look at the key differences between the Wegovy pill vs. Foundayo:
| Foundayo | Wegovy pill |
Active ingredient | Orforglipron | Semaglutide |
FDA-approved indications | Weight loss in adults with obesity or overweight | Weight loss in adults with obesity or overweight
Reduced cardiovascular risk in adults with heart disease and obesity or overweight |
Frequency | Daily | Daily |
Administration | Swallowed whole with or without food at the same time each day
| Swallowed whole on an empty stomach at least 30 minutes before eating, drinking, or taking other medications |
Dosage strengths | 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg | 1.5 mg, 4 mg, 9 mg, 25 mg |
Effectiveness | Average 7.5%–11.2% in 72 weeks, depending on dose | Average 13.6% weight loss in 64 weeks |
Side effects | Nausea, constipation, diarrhea, vomiting, stomach pain or upset, bloating, headache, fatigue, heartburn, gas, hair loss | Nausea, diarrhea, vomiting, constipation, stomach pain or upset, dizziness, headache, fatigue, heartburn, gas, hair loss |
Cost (without insurance) | $149–$299* per month, depending on dose (cash price) | $1,349.02 (list price) $149–$299* per month, depending on dose (cash price) |
*Terms and restrictions may apply for certain doses of the pill.
Foundayo vs. Wegovy pill: how they’re taken and absorbed
Foundayo and the Wegovy pill are both taken daily, but there are key differences in how they’re meant to be taken and how they’re absorbed by the body.
Administration
The Wegovy pill has stricter requirements around when and how you take your dose than Foundayo.
Foundayo can be taken with or without food at any time of day. It should be swallowed whole. There’s no “best” time of day to take Foundayo, but taking it around the same time each day can help make it a consistent part of your routine.
The Wegovy pill must be taken on an empty stomach in the morning, at least 30 minutes before food, beverages, and other oral medications. It should be swallowed whole with up to 4 ounces of plain water.
Absorption
As a non-peptide, Foundayo has a smaller molecular structure. This allows it to be better absorbed in the gut and taken with or without food, unlike the Wegovy pill, which is a peptide (like most GLP-1s) and must be taken on an empty stomach.
These differences in absorption affect how quickly Foundayo and Wegovy start working and their bioavailabilities (i.e. how much of the active ingredient becomes available in your bloodstream).
Wegovy starts working sooner. It takes about 4–8 hours for Foundayo to reach its peak concentration in your bloodstream. Meanwhile, it only takes Wegovy an hour.
Foundayo has a higher bioavailability. Because it’s not as vulnerable to breakdown as oral Wegovy, Foundayo has a bioavailability of 77%, while Wegovy’s is only 1%–2%.
Which is more effective for weight loss: Foundayo or Wegovy pill?
The Wegovy pill is a bit more effective for weight loss than Foundayo, according to separate studies. Still, Foundayo’s weight loss results are nothing to scoff at.
In clinical trials of Foundayo, the drug produced an average weight loss of up to 11.2% in 72 weeks (~a year and 4–5 months). If your starting weight is 250 pounds, that’s a loss of 28 pounds.
In clinical trials of the Wegovy pill, the drug produced an average weight loss of 13.6% in 64 weeks (~a year and three months). If your starting weight is 250 pounds, that’s a loss of 34 pounds.
Note that both studies included people without diabetes. People with type 2 diabetes tend to lose less weight on semaglutide compared to those without diabetes. In this group, the Wegovy tablet can lead to lower and less consistent levels of the medication. So it may not work as well — meaning the injection might be a better option for those with type 2 diabetes.
Foundayo vs. Wegovy pill: doses and dosage schedules
Foundayo and the Wegovy pill are both taken daily. They come in different dosage strengths:
Foundayo comes in six dosage strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg. The recommended maintenance dosage is 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg, depending on your response to the medication.
The Wegovy pill comes in four dosage strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg. The recommended maintenance dosage is 25 mg daily.
Foundayo and the Wegovy pill both follow gradual titration schedules, slowly increasing the dosage to give your body time to adjust. You typically start by taking a low dose of the drug and slowly increase the dose until you reach a maintenance dose that works for you.
For these oral GLP-1s, dosage increases typically happen every 30 days. But your healthcare provider may titrate you more slowly based on your response to the medication and tolerance for side effects.
Here’s a general dosing schedule of both drugs:
Timeframe | Foundayo dosage | Wegovy pill dosage |
Days 1–30 | 0.8 mg once daily | 1.5 mg once daily |
Days 31–60 | 2.5 mg once daily | 4 mg once daily |
Days 61–90 | 5.5 mg once daily | 9 mg once daily |
Days 91–120 | 9 mg once daily | 25 mg once daily |
Days 121–150 | 14.5 mg once daily | 25 mg once daily |
Days 151+ | 17.2 mg once daily | 25 mg once daily |
Because Foundayo has more maintenance dosage options than Wegovy, it may take you more (or less) time to reach your maintenance dosage of the medication.
In contrast, the Wegovy pill has one maintenance dosage option: 25 mg daily. If you have trouble tolerating 25 mg, your prescriber may recommend switching to the Wegovy 1.7 mg weekly injection instead.
Foundayo vs. Wegovy pill: side effects and risks
As GLP-1 medications, Foundayo and the Wegovy pill share similar side effects. These tend to be gastrointestinal in nature, ranging from mild to moderate in intensity. They’re usually at their worst when starting the medication and when increasing your dose.
The Wegovy pill and Foundayo share the following common side effects:
Vomiting
Stomach pain, bloating, or upset
Gas (belching, flatulence)
Less commonly, both Foundayo and the Wegovy pill may cause additional side effects, including:
Prickling, numbness, or tingling sensations in the skin (although the risk is notably higher with the Wegovy HD injection)
Dizziness
Hypoglycemia (low blood sugar)
Stomach flu-like symptoms
Increased heart rate
Both Foundayo and the Wegovy pill carry similar risks, including:
Acute pancreatitis
Allergic reaction to the medication
Kidney or gallbladder problems
Severe hypoglycemia (low blood sugar), especially in people taking certain diabetes medications
Severe gastrointestinal reactions resulting in dehydration
Diabetic retinopathy (diabetes-related vision loss or changes) in people with type 2 diabetes
Pulmonary aspiration (inhaled stomach contents) during general anesthesia or deep sedation
Finally, both weight loss medications carry a boxed warning for thyroid cancer based on animal studies. While it’s not known if the risk is the same in humans, neither Foundayo nor Wegovy should be taken by people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
People who are pregnant, breastfeeding, or planning to conceive also should not take Wegovy or Foundayo.
Foundayo vs. Wegovy pill: how much do they cost?
When purchased without insurance, Foundayo and the Wegovy pill cost about the same. Specific prices vary depending on the dose, with higher doses costing more than lower doses.
Foundayo costs $149–$299 per month, depending on dosage strength, when paying cash on Ro.
The Wegovy pill costs $149–$299 per month, depending on dosage strength, when paying cash on Ro.
The Wegovy pill also has a list price of $1,349.02. Meaning, it can cost thousands of dollars when you pay out-of-pocket without a discount card at your local pharmacy.
If you have insurance, however, it can be a different story. Both Foundayo and the Wegovy pill can cost even less if your insurance plan covers them, thanks to each pill’s manufacturer savings offer. Either pill can cost as low as $25 per month with these offers, so long as you have a commercial insurance plan that covers Wegovy or Foundayo.
People with government-funded insurance, such as Medicare or Medicaid, are not eligible for these savings offers.
Foundayo vs. Wegovy pill: drug interactions
Foundayo and Wegovy tablets both interact with other medications, but in different ways.
Some medications can raise or lower Foundayo’s levels — and Foundayo can affect other drugs, as well. So your provider may adjust doses or avoid certain combinations. A few examples:
If you take the antibiotic clarithromycin (Biaxin), Foundayo is typically limited to a maximum of 9 mg daily.
If you take Foundayo with simvastatin (a cholesterol medication), the simvastatin dose is usually limited to 20 mg daily.
Foundayo should not be used with ritonavir (an antiviral drug), as it can raise Foundayo levels too much.
If you take oral birth control pills, Foundayo may make them less effective. Because of this, you should switch to a non-oral method (e.g. IUD, patch) or use a backup method, such as condoms, for 30 days after starting Foundayo and for 30 days after each dose increase.
With Wegovy tablets, interactions are more about timing. For oral Wegovy to work properly, you must take it on an empty stomach and wait at least 30 minutes before taking any other oral pills.
Both Foundayo and Wegovy may increase the risk of low blood sugar when used with insulin or certain diabetes pills, such as glipizide or glyburide. Your provider may adjust the dose of diabetes medications or tell you to monitor your blood sugar more often.
Your healthcare provider may factor in your other medications when choosing the best option. Always share everything you take, including supplements.
Can you switch between Foundayo and the Wegovy pill?
Yes, you can generally switch between GLP-1 medications, including Foundayo and the Wegovy pill — as long as it’s done under the guidance and care of a healthcare provider.
Some people tolerate one medication better than another, or your GLP-1 insurance coverage changes. Your healthcare provider will guide you on how to manage the switch to ensure a smooth transition and keep side effects to a minimum.
Their guidance may depend on how long you’ve been taking Foundayo or the Wegovy pill:
If you’ve been taking Foundayo or the Wegovy pill for less than a month, they may have you start from scratch at the lowest dose of the other pill.
If you’ve been taking Foundayo or the Wegovy pill for more than a month, they may still have you start from scratch. But if you were already taking a maintenance dose of Foundayo or the Wegovy pill, they may start you at a slightly higher dosage than the absolute lowest one.
Usually, the switch can start as soon as the next day. Instead of taking Wegovy or Foundayo, you simply start the new medication at the usual time. However, if you’re switching due to intolerable side effects, your healthcare provider may have you wait until those side effects subside before switching you to the new medication.
How to choose between Foundayo and the Wegovy pill
Both Foundayo and the Wegovy pill are considered to be safe and effective weight loss pills. Your healthcare provider can help you find the best choice for you, based on your lifestyle, weight loss goals, and current health situation. Here are some factors to consider when deciding between Foundayo vs. the Wegovy pill:
Foundayo may be better if:
You’re okay with more moderate weight loss results
Your schedule changes from day to day and you want more flexibility around when you take your dose
You’re worried about experiencing side effects that are more common with Wegovy, such as dizziness or increased heart rate
Your insurance offers better coverage for Foundayo
The Wegovy pill may be better if:
You want larger weight loss results
You have a consistent morning routine and don’t mind waiting 30 minutes before eating, drinking, or taking other medication after your dose
You also have heart disease and want to lower your cardiovascular risk
Your insurance offers better coverage for Wegovy
You take other medications that interact with Foundayo
Bottom line
If you’re considering asking your doctor for weight loss pills, here's the high-level breakdown between Foundayo vs. the Wegovy pill.
You can lose more weight on Wegovy, but it has a stricter dosing schedule. Foundayo offers more flexibility as it can be taken at any time of day, with or without food, but it can produce slightly less weight loss (11.2% vs. 13.6%).
Both Foundayo and the Wegovy pill have a cash price of $149–$299 per month, depending on dose, on Ro. Lower dosage strengths cost less.
Since both are GLP-1s, the pills have similar side effects and risks, which are usually GI-related. However, Wegovy can also cause an increased heart rate.
Frequently asked questions (FAQs)
Can you switch between the Wegovy pill and Foundayo?
Yes, you can generally switch between different GLP-1 medications, such as the Wegovy pill and Foundayo. That is, however, as long as it’s done under the guidance and supervision of a healthcare provider. Depending on your current dose of Wegovy, you may need to start at a lower dose of Foundayo and titrate up from there.
What is the new weight loss pill from Eli Lilly?
As of publication, Foundayo is the new weight loss pill from Eli Lilly. In clinical trials, people taking Foundayo lost up to 11.2% of their starting body weight in less than a year and a half. Foundayo is taken once daily, with or without food. Common side effects include nausea, constipation, diarrhea, vomiting, and upset stomach.
Is Foundayo as good as the Wegovy pill?
The Wegovy pill generally leads to slightly more weight loss (13.6%) than Foundayo (11.2%), according to separate studies. However, Foundayo offers more convenience than the Wegovy pill, as it can be taken at any time of day, with or without food. The Wegovy pill must be taken in the morning on an empty stomach and requires fasting for 30 minutes after taking the pill.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
Foundayo Important Safety Information: Read more about serious warnings and safety info.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
References
Almandoz, J. P., Lingvay, I., Morales, J., et al. (2020). Switching between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical guidance. Clinical Diabetes, 38(4), 390–402. doi: 10.2337/cd19-0100. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7566932/
Eli Lilly-a. (2026). Coverage & Savings for Foundayo. Retrieved from https://foundayo.lilly.com/coverage-savings
Eli Lilly-b. (2026). Foundayo(orforglipron): Now accepting prescriptions. Retrieved from https://www.lilly.com/lillydirect/medicines/foundayo
Eli Lilly-c. (2026). News Release: FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. Retrieved from https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
Eli Lilly-d. (2026). What effect did Foundayo (orforglipron) have on body weight in phase 3 studies for weight management?. Retrieved from https://medical.lilly.com/us/products/answers/what-effect-did-foundayo-orforglipron-have-on-body-weight-in-phase-3-studies-for-weight-management-366872
Gabe, M. B. N., Breitschaft, A., Knop, F. K., et al. (2024). Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes, Obesity & Metabolism, 26(10), 4480–4489. doi: 10.1111/dom.15802. Retrieved from https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15802
Jain, A. B., Ali, A., Martínez, J. J. G., et al. (2020). Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance. International Journal of Clinical Practice, 75(2), e13731. doi: 10.1111/ijcp.13731. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7900946/
Ma, X., Liu, R., Pratt, E. J., et al. (2024). Effect of food consumption on the pharmacokinetics, safety, and tolerability of Once-Daily orally administered orforglipron (LY3502970), a non-peptide GLP-1 receptor agonist. Diabetes Therapy, 15(4), 819–832. doi: 10.1007/s13300-024-01554-1. Retrieved from https://link.springer.com/article/10.1007/s13300-024-01554-1
NovoCare-a. (2026). Price guide. Novo Nordisk. Retrieved from https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
NovoCare-b. (2026). Price your Wegovy. Novo Nordisk. Retrieved from https://www.novocare.com/patient/medicines/wegovy.html
NovoCare-c. (2026). Start saving on Wegovy. Novo Nordisk. Retrieved from https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
Pratt, E., Ma, X., Liu, R., et al. (2023). Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes, Obesity & Metabolism, 25(9), 2634–2641. doi: 10.1111/dom.15184. Retrieved from https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15184
U.S. Food and Drug Administration (FDA-a). (2026). Prescribing Information: Foundayo (orforglipron) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf
U.S. Food and Drug Administration (FDA-b). (2026). Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use; Wegovy (semaglutide) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s005lbl.pdf
Wharton-a, S., Blevins, T., Connery, L., et al. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine, 389(10), 877–888. doi: 10.1056/nejmoa2302392. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2302392?url_ver=Z39.88-2003
Wharton-b, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. The New England Journal of Medicine, 393(11), 1077–1087. doi: 10.1056/NEJMoa2500969. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40934115/
Wharton-c, S., Aronne, L. J., Stefanski, A., et al. (2025). Orforglipron, an oral Small-Molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine, 393(18), 1796–1806. doi: 10.1056/nejmoa2511774. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2511774?url_ver=Z39.88-2003















